Patent · US Active

B-lymphocyte specific amatoxin antibody conjugates

US12403201B2 · kind B2 · utility

0Cited by

9References

8Claims

0Family size

Assignee

Heidelberg Pharma Research GmbH · DE

Inventors

Torsten Hechler · Ladenburg, DE
Michael Kulke · Ladenburg, DE
Andreas Pahl · Ladenburg, DE

Key dates

Filing date	Mar 17, 2022
Grant date	Sep 2, 2025
Priority date	—
Expiry date	Mar 17, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to conjugates comprising an amatoxin a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.